172 related articles for article (PubMed ID: 10632743)
21. Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma.
Liu N; Aldea S; François D; Cherqui-Michel M; Giansily-Blaizot M; Fischler M
Br J Anaesth; 2009 Dec; 103(6):858-60. PubMed ID: 19846405
[TBL] [Abstract][Full Text] [Related]
22. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
23. Inhibitor development after liver transplantation in congenital factor VII deficiency.
See WS; Chang KO; Cheuk DK; Leung YY; Chan GC; Chan SC; Ha SY
Haemophilia; 2016 Sep; 22(5):e417-22. PubMed ID: 27501477
[TBL] [Abstract][Full Text] [Related]
24. Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.
Tokgoz H; Caliskan U; Lavigne-Lissalde G; Giansily-Blaizot M
Haemophilia; 2012 Jan; 18(1):e25-7. PubMed ID: 21973016
[No Abstract] [Full Text] [Related]
25. Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
Mullighan CG; Rischbieth A; Duncan EM; Lloyd JV
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):347-51. PubMed ID: 15166922
[TBL] [Abstract][Full Text] [Related]
26. rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency.
Tran HT; Tjønnfjord GE; Paus A; Holme PA
Haemophilia; 2011 Sep; 17(5):764-70. PubMed ID: 21707871
[TBL] [Abstract][Full Text] [Related]
27. Factor VIIa replacement therapy in factor VII deficiency.
Brummel Ziedins K; Rivard GE; Pouliot RL; Butenas S; Gissel M; Parhami-Seren B; Mann KG
J Thromb Haemost; 2004 Oct; 2(10):1735-44. PubMed ID: 15456484
[TBL] [Abstract][Full Text] [Related]
28. Factor VII Deficiency.
Mariani G; Bernardi F
Semin Thromb Hemost; 2009 Jun; 35(4):400-6. PubMed ID: 19598068
[TBL] [Abstract][Full Text] [Related]
29. Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding.
Andersen E; Chollet ME; Sletten M; Stavik B; Skarpen E; Backe PH; Thiede B; Glosli H; Henriksson CE; Iversen N
Thromb Haemost; 2021 Dec; 121(12):1588-1598. PubMed ID: 33742435
[TBL] [Abstract][Full Text] [Related]
30. Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients.
Shams M; Dorgalaleh A; Safarian N; Emami AH; Zaker F; Tabibian S; Managhchi MR; Faranoush M; Tabatabaei T; Satari S; Rezvani MR
Blood Coagul Fibrinolysis; 2019 Jan; 30(1):24-28. PubMed ID: 30585836
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.
Berrettini M; Mariani G; Schiavoni M; Rocino A; Di Paolantonio T; Longo G; Morfini M
Haematologica; 2001 Jun; 86(6):640-5. PubMed ID: 11418374
[TBL] [Abstract][Full Text] [Related]
32. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency.
Farah RA; Hamod D; Melick N; Giansily-Blaizot M; Sallah S
J Thromb Haemost; 2007 Feb; 5(2):433-4. PubMed ID: 17109737
[No Abstract] [Full Text] [Related]
33. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven).
Johannessen M; Nielsen G; Nordfang O
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S159-64. PubMed ID: 10850583
[TBL] [Abstract][Full Text] [Related]
34. NovoSeven as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S107-11. PubMed ID: 10850574
[TBL] [Abstract][Full Text] [Related]
35. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
Mathijssen NC; Masereeuw R; Holme PA; van Kraaij MG; Laros-van Gorkom BA; Peyvandi F; van Heerde WL
Thromb Res; 2013 Aug; 132(2):256-62. PubMed ID: 23834817
[TBL] [Abstract][Full Text] [Related]
36. Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis.
Niikura T; Nishikawa T; Saegusa Y; Fujishiro T; Yoshiya S; Kurosaka M
J Arthroplasty; 2005 Apr; 20(3):396-400. PubMed ID: 15809961
[TBL] [Abstract][Full Text] [Related]
37. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
38. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options.
Lapecorella M; Mariani G;
Haemophilia; 2008 Nov; 14(6):1170-5. PubMed ID: 19141157
[TBL] [Abstract][Full Text] [Related]
39. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
[TBL] [Abstract][Full Text] [Related]
40. Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.
Cramer TJ; Anderson K; Navaz K; Brown JM; Mosnier LO; von Drygalski A
Blood Cells Mol Dis; 2016 Mar; 57():8-12. PubMed ID: 26852649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
